|
|
Article: Tenofovir DF Expanded Access.(patient access extended)
- Article from:
- AIDS Treatment News
- Article date:
- February 23, 2001
CopyrightCOPYRIGHT 2001 John S. James. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
On February 1 Gilead Sciences announced a much-enlarged expanded access program for tenofovir DF (tenofovir diisoproxil fumarate), a potentially important new drug which is now in a phase III clinical trial with over 500 treatment experienced patients (averaging more than five years of HIV treatment before beginning this trial). The new pre-approval program is limited to "patients who have failed commercially available antiretroviral treatment ...